Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764108 | 0.90 | CA2 (0.36) | CA2CHKAKDM4EMAPTKMT2A | |
| SCHEMBL1794347 | 0.87 | — | — | |
| SCHEMBL28062708 | 0.85 | CA2 (0.41) | CA2CHKAKDM4ECA12CA1 | |
| SCHEMBL250579 | 0.85 | CA2 (0.38) | CA2CHKACHRNB2CHRNA4CA12 | |
| SCHEMBL1242860 | 0.84 | L3MBTL1 (0.38) | CA2CHKAALDH1A1MAPTCA1 | |
| SCHEMBL16616375 | 0.83 | CA2 (0.37) | CA2CHKACHRNB2CHRNA4CA12 | |
| Hydrochloric Acid SCHEMBL3873748 | 0.82 | L3MBTL1 (0.37) | ALDH1A1 | |
| SCHEMBL790285 | 0.82 | — | — | |
| Azepane SCHEMBL15135390 | 0.78 | CA2 (0.41) | CA2CHKAALDH1A1KDM4E | |
| SCHEMBL5149419 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655640-B2 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-02-02 | — | — | US | disclosed |
| US-7514418-B2 | Camptothecin analogs and methods of preparation thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1017399-B1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080269169-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| EP-1140948-A4 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070259905-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-08 | — | — | US | disclosed |
| US-7271159-B2 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| US-6743917-B2 | 7-(TRIALKYLSILYLALKYL)-CAMPTOTHECIN OF GIVEN FORMULA BY CYCLIZING A 4-HYDROXY-6-HALO,7-(TRIALKYLSILYLALKYL)-3,4,7,8-TETRAHYDRO-1H-PYRANO(3,4 -C)PYRIDIN-3,8-DIONE WITH AN ARYL ISONITRILE | UNIVERSITY OF PITTSBURGH | 2004-06-01 | — | — | US | disclosed |
| US-6455699-B1 | SUCH AS (20S)10-HYDROXY-7-TERT-BUTYLDIMETHYLSILYL-CAMPHTOTHECIN; ANTITUMOR AGENTS; SOLUBILITY; BIOAVAILABILITY/ BIODISTRIBUTION | UNIVERSITY OF PITTSBURGH | 2002-09-24 | — | — | US | disclosed |
| EP-1140948-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6150343-A | 10-HYDROXY-7-SUBSTITUTED SILYLCAMPTOTHECIN DERIVATIVE IS USED AS ANTICARCINOGENIC AND ANTITUMOR AGENT | UNIVERSITY OF PITTSBURGH (US) | 2000-11-21 | — | — | US | disclosed |
| US-6136978-A | CYCLIZING SILYL COMPOUND WITH ARYL ISONITRILE COMPOUND TO FORM SILYL CAMPTOTHECIN DERIVATIVE | UNIVERSITY OF PITTSBURGH (US) | 2000-10-24 | — | — | US | disclosed |
| WO-2000035924-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259905-A1 | Camptothecin analogs and methods of preparation thereof | ADCY9, BCL9, ADCY10 | CA2 2154/4885CHKA 460/4885ALDH1A1 1767/4885 |
| US-20080269169-A1 | Camptothecin analogs and methods of preparation thereof | TOP2A, TOP1, TOP2B | CA2 2348/4885CHKA 1010/4885ALDH1A1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.